-
02:19:42 AM
Trending News

Covid-19 News LIVE

The stock market news feed is automatically updated to show the latest 50 news.
The news is in real time for GOLD users while a 15 second delay is applied for FREE users.

Become a Gold member to unlock the feed filters, voice notification and see the news without delay.

Check out our Stock Market News Today and Join our Discord

01/24/23 9:30 AM
Nasdaq : CODX
covid-19
Co-Diagnostics, Inc. Commemorates Third Anniversary of the Completion of its First COVID-19 Test Design
Co-Diagnostics also announced today that it would be hosting a booth at the upcoming BioHive and BioUtah Life Sciences Day on the Hill, on January 27, 2023 from 11:00 AM to 2:00 PM at the Utah State Capitol rotunda. The annual event showcases Utah's life sciences industry as one of the fastest growing in the nation, and the Company's booth is expected to...
RHEA-AI
neutral
01/24/23 8:30 AM
Nasdaq : DYAI
clinical trialcovid-19low float
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced
RHEA-AI
neutral
01/23/23 8:30 AM
Nasdaq, NYSE : DOGZ, BQ
covid-19
Dogness Benefits from Rebound in Pet Product Sales in Australian Market; Latest Market to Benefit from Post-COVID Reopening
Dogness Corporation, a developer and manufacturer of a comprehensive line of Dogness- branded, OEM/ODM and private label pet products, today announced it is benefitting from a significant rebound in pet product sales in the Australian market. Our commitment to developing attractive, high-quality products that ensure comfort to pets and sought after...
RHEA-AI
very positive
01/19/23 4:50 PM
OTC : RVVTF
clinical trialcovid-19
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that it has
RHEA-AI
neutral
01/19/23 12:00 PM
Nasdaq : GTH, TRIB
covid-19
COVID-19 Pandemic Emphasized the Importance of In Vitro Diagnostics, More than $127 Billion Worth Market Opportunity in the IVD Market - Arizton
According to Arizton's latest research report, the i n-vitro diagnostics market will grow at a CAGR of 3.3% from 2022-2028. In recent years, IVD diagnostics has been one of the biggest industries that observed several product launches. In 2022, North America accounted for the largest share of 40% of the global IVD market. The patient population with high...
RHEA-AI
neutral
01/19/23 9:05 AM
NYSE : CHGG
covid-19
Chegg Announces Inaugural Student Mental Health Week to Address Growing Student Anxiety in the Age of Covid and Beyond
Chegg, Inc., today announced that it has partnered with five esteemed non-profits to establish Student Mental Health Week from February 6 to February 12, 2023. The inaugural global initiative, which Chegg plans to run annually, seeks to destigmatize mental health among students, encourage young people to be intentional about looking after themselves, and...
RHEA-AI
neutral
01/18/23 2:02 PM
Nasdaq : HSTO
covid-19low float
Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration
Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19. On October 27, 2020, Amerimmune LLC entered into a development Agreement with Histogen Inc. to jointly develop Emricasan as a potentially promising treatment for COVID-19. Histogen Inc. filed for...
RHEA-AI
neutral
01/12/23 1:14 PM
OTC : RVVTF
clinical trialcovid-19
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces it will submit an
RHEA-AI
neutral
01/09/23 9:00 AM
Nasdaq : SRNE
clinical trialcovid-19
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the doses from 300 mg to 2,000 mg in 32 healthy volunteers and the multiple ascending dose (MAD) portion of the study in
RHEA-AI
neutral
01/09/23 8:05 AM
AMEX : AIM
covid-19
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the
RHEA-AI
neutral
01/09/23 6:00 AM
Nasdaq : OCGN
clinical trialcovid-19high short
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
Study met both co-primary endpoints with robust immune responses COVAXIN ™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the United States (U.S.), with no vaccine-related serious adverse events, thrombotic events, or cases
RHEA-AI
negative
01/05/23 7:30 AM
Nasdaq : IFRX
covid-19
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient number between approximately 50 and 100 patients FDA review of application for emergency use
RHEA-AI
neutral
12/21/22 3:08 PM
OTC : RHHBY
fda approvalcovid-19
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved Actemra ® intravenous for the treatment of COVID-19 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane...
RHEA-AI
very positive
12/21/22 7:30 AM
Nasdaq : IFRX
covid-19
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in China STS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’s
RHEA-AI
positive
12/16/22 7:30 AM
Nasdaq : MRNA
covid-19
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union
The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4-5)) are approved for use in individuals 12 years of age and older in the European
RHEA-AI
neutral
12/15/22 10:30 AM
NYSE : RAD
covid-19
Scheduling for Updated COVID-19 Dose for Children Ages Three and Older Now Available at Select Rite Aid and Bartell Drugs locations
Following FDA authorization and new CDC recommendations, select Rite Aid locations, including Bartell Drugs in the Pacific Northwest, are now offering the Pfizer-BioNTech bivalent COVID-19 Vaccine to children ages 3 and over. Rite Aid pharmacists are trained to administer vaccines 3 and older. “Approval of the updated vaccine for our pediatric population...
RHEA-AI
neutral